<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701764</url>
  </required_header>
  <id_info>
    <org_study_id>20160095</org_study_id>
    <nct_id>NCT02701764</nct_id>
  </id_info>
  <brief_title>Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?</brief_title>
  <official_title>Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can Lyrica (Pregabalin) help prevent severe Dry Eye post LASIK surgery?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dry eye symptoms can occur after LASIK surgery. They generally get better with time but in
      some patients, they can persist. The investigators believe that in some individuals, dry eye
      symptoms after LASIK persist because the nerves in the cornea become hypersensitive. The
      investigators wish to study if a medication, called pregabalin, can protect corneal nerves at
      the time of LASIK surgery and decrease the frequency and severity of dry eye symptoms 6
      months after surgery. This medication has been used in a similar way to reduce the frequency
      of uncomfortable sensations after other surgeries (knee, abdomen) but has never been studied
      in LASIK surgery.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 26, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of dry eye symptoms</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of dry eye symptoms (DEQ5)</measure>
    <time_frame>6 months</time_frame>
    <description>Dry eye questionnaire 5- validated dry eye symptom questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear production measured by Schirmers strips</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear evaporation measured by tear break up time</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve fiber density measured by confocal microscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 and 65 years of age

          -  undergoing LASIK (unilateral or bilateral procedure).

          -  Females of child-bearing age will need a negative urine or serum pregnancy test at the
             screening visit.

          -  ocular and systemic medication regimen has been stable for 3 months

        Exclusion Criteria:

          -  Pregnant or lactating, participating in another study with an investigational drug
             within one month prior to screening

          -  Using gabapentin, pregabalin, anti-convulsants, duloxetine, venlafaxine (SNRI), or
             tri-cyclic antidepressants

          -  have a history of allergic, anaphylactic reaction, or severe systemic response to
             pregabalin or gabapentin

          -  use corticosteroids chronically or during the month prior to surgery, or have a
             history of corneal disease (HSV or varicella zoster keratitis, prior corneal incisions
             (cataract surgery, radial keratotomy, LASIK), prior corneal ulcer).

          -  patients with systemic co-morbidities that may confound DE such as HIV, sarcoidosis,
             graft-versus host disease or a collagen vascular disease.

          -  Adults unable to consent

          -  Individuals who are not yet adults (infants, children, teenagers)

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anat Galor, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anat Galor</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Levitt AE, Galor A, Weiss JS, Felix ER, Martin ER, Patin DJ, Sarantopoulos KD, Levitt RC. Chronic dry eye symptoms after LASIK: parallels and lessons to be learned from other persistent post-operative pain disorders. Mol Pain. 2015 Apr 21;11:21. doi: 10.1186/s12990-015-0020-7. Review.</citation>
    <PMID>25896684</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Anat Galor</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>laser-assisted in situ keratomileusis</keyword>
  <keyword>dry eye symptoms</keyword>
  <keyword>LASIK</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

